Company Profile

Concert Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on developing CTP-543, a Janus Kinase 1 and Janus Kinase 2 (JAK 1/2) inhibitor that discovered through deuterated chemical entity Platform (DCE platform). The Company is evaluating CTP-543 in a Phase III clinical program for the treatment of alopecia areata, a serious autoimmune dermatological condition. Through DCE Platform, the Company has discovered and developed novel drugs designed to have properties, including enhanced clinical safety, tolerability or efficacy based on compounds. DCE technology has range of potential across numerous therapeutic areas, including for chronic diseases for which medicines are continually used by patients. The Company is assessing earlier-stage pipeline candidates as potential development candidates, including a once-daily, modified release formulation of CTP-543.

Employees

Sector

Biotechnology & Medical Research

More about the company

01-28	Omass Therapeutics Announces Board Changes	CI
23-03-18	Concert Pharmaceuticals Announces the Presentation of Data from its Phase 3 Clinical Trial, THRIVE-AA2	CI
23-03-06	Sun Pharmaceutical Completes Acquisition of Concert Pharmaceuticals	MT
23-03-06	Concert Pharmaceuticals, Inc.(NasdaqGM:CNCE) dropped from NASDAQ Composite Index	CI
23-03-06	Concert Pharmaceuticals, Inc.(NasdaqGM:CNCE) dropped from S&P Global BMI Index	CI
23-03-06	Concert Pharmaceuticals, Inc.(NasdaqGM:CNCE) dropped from S&P TMI Index	CI
23-03-05	Sun Pharmaceutical Industries Limited completed the acquisition of Concert Pharmaceuticals, Inc..	CI
23-03-03	Concert Pharmaceuticals, Inc.(NasdaqGM:CNCE) dropped from NASDAQ Biotechnology Index	CI
23-02-15	Concert Pharmaceuticals Says Deuruxolitinib Maintains FDA Breakthrough Therapy Designation to Treat Alopecia Areata	MT
23-02-15	Concert Pharmaceuticals, Inc. Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata	CI
23-01-31	Insider Sell: Concert Pharmaceuticals	MT
23-01-20	JMP Securities Downgrades Concert Pharmaceuticals to Market Perform From Market Outperform	MT
23-01-20	Truist Downgrades Concert Pharmaceuticals to Hold Rating From Buy, Adjusts Price Target to $9 From $25	MT

23-01-20	JMP Securities Downgrades Concert Pharmaceuticals to Market Perform From Market Outperform	MT
23-01-20	Truist Downgrades Concert Pharmaceuticals to Hold Rating From Buy, Adjusts Price Target to $9 From $25	MT
23-01-20	Jefferies Downgrades Concert Pharmaceuticals to Hold From Buy, Adjusts Price Target to $9 From $15	MT
23-01-20	JonesTrading Downgrades Concert Pharmaceuticals to Hold From Buy	MT
22-09-13	Truist Securities Increases Price Target on Concert Pharmaceuticals to $25 From $22, Maintains Buy Rating	MT

23-09-27	Alopecia Areata Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 (Updated)	AQ
23-03-20	SUN PHARMA - LATE-BREAKING PHASE 3 DATA AT AAD 2023 SHOW ORAL INVESTIGATIONAL MEDICINE DEURUXOLITINIB SIGNIFICANTLY IMPROVED SCALP HAIR REGROWTH IN ALOPECIA AREATA	AQ
23-03-06	CONCERT PHARMACEUTICALS, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
23-02-15	Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata	BU
23-01-20	CONCERT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Concert Pharmaceuticals, Inc. - CNCE	BU

Date	Insider	Type	Main position	Quantity	% Market Cap.
3/6/23	Marc A. Becker	Tender	Chief Financial Officer	428,143	0.8915%
3/6/23	Christine van Heek	Tender	Director	128,448	0.2675%
3/6/23	James Cassella	Tender	Chief Development Officer	660,391	1.3752%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CONCERT PHARMACEUTICALS, INC.	+0.12%	-0.36%	-	-	521M
LONZA GROUP AG	-1.78%	-1.68%	+1.48%	+15.31%	48.42B
REVOLUTION MEDICINES, INC.	+0.85%	-0.70%	+460.88%	+563.55%	43.66B
BEONE MEDICINES AG	-2.40%	-0.23%	+8.13%	+71.41%	39.51B
IQVIA HOLDINGS INC.	-2.01%	-0.85%	+23.85%	+8.73%	38.95B
CELLTRION, INC.	-0.50%	+0.85%	+20.60%	+49.65%	32.61B
ASCENDIS PHARMA A/S	+0.38%	-3.23%	-	-	16.32B
MEDPACE HOLDINGS, INC.	-0.59%	-2.06%	+26.35%	+118.09%	16.15B
EUROFINS SCIENTIFIC SE	+0.49%	+0.92%	+4.11%	+23.67%	14.16B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.43%	+4.70%	+78.74%	+33.31%	13.37B
Average	-0.59%	+0.49%	+78.02%	+110.46%	29.24B
Weighted average by Cap.	-0.91%	+0.59%	+95.83%	+132.95%

Concert Pharmaceuticals, Inc. Stock

Stocks

CNCE

US2060221056

Biotechnology & Medical Research

Latest news : Concert Pharmaceuticals, Inc.

Analysts' recommendations: Concert Pharmaceuticals, Inc.

Press Releases: Concert Pharmaceuticals, Inc.

Quotes and Performance

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile